Delwa-Star WS-FM Blood Pressure and Body Fat Monitor
by Zewa, Inc.
510(k) K024077
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK024077 | Date10 Mar 2003 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- DXN
- Device Class
- Class II
- Regulation
- 21 CFR Part 870.1130
- Advisory Committee
- Cardiovascular
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
The Delwa-Star WS-FM Blood Pressure and Body Fat Monitor is a non-invasive, fully automatic wrist-based device designed for measuring systolic and diastolic blood pressure, pulse rate, and body fat percentage. Classified under the FDA’s product code DXN as a System, Measurement, Blood-Pressure, Non-Invasive device, it falls within the Cardiovascular specialty category. The monitor utilises an inflatable wrist cuff to obtain readings, providing quantitative data for cardiovascular assessment and body composition analysis.
This device is intended for use by adults with moderately active to inactive lifestyles and is supplied as a single-unit, non-sterile medical instrument. It requires no special regulatory sterility standards beyond general hygiene practices for home use. The monitor operates independently and does not require connection to external systems or MRI compatibility considerations. Storage instructions are not specified in the regulatory data, but standard environmental conditions for medical devices should be followed. Authorised for commercial distribution in the United States under FDA 510(k) clearance (K024077) as Substantially Equivalent (SESE)
Other devices from Zewa, Inc.
Questions
AI-generated answers, 1 Oct 2026
What is the Delwa-Star WS-FM Blood Pressure and Body Fat Monitor used for?
This device is designed for non-invasive, automatic measurement of systolic and diastolic blood pressure, pulse rate, and body fat percentage. It provides quantitative data useful for assessing cardiovascular health and body composition in adults with moderately active to inactive lifestyles. The inflatable wrist cuff ensures accurate readings without requiring external connections or specialized equipment.
How is the Delwa-Star WS-FM supplied and what are its sterility requirements?
The monitor is supplied as a single-unit, non-sterile device intended for home use. Since it is not classified as a sterile medical instrument, standard hygiene practices—such as regular cleaning with mild soap and water—are recommended to maintain functionality and prevent contamination. No specialized regulatory sterility standards apply beyond general cleanliness.
Is the Delwa-Star WS-FM reusable or single-use?
The device is intended for repeated use by individual consumers in a home setting. Unlike single-use instruments, it is designed to provide ongoing measurements over time, provided it is properly maintained according to manufacturer guidelines. There are no regulatory restrictions on reuse, but users should follow basic care instructions to ensure accuracy and longevity.
What storage conditions should be followed for this monitor?
While specific storage instructions are not detailed in regulatory data, the device should be stored under standard environmental conditions for medical devices. This typically means keeping it in a dry, clean environment away from direct sunlight, extreme temperatures, or moisture. Avoid placing it in areas prone to physical damage or contamination, such as bathrooms or near cleaning chemicals.
What regulatory approval does the Delwa-Star WS-FM hold?
The device holds FDA 510(k) clearance under the product code DXN, classified as a non-invasive blood pressure measurement system. It was determined *Substantially Equivalent* (SESE) to a predicate device and authorized for commercial distribution in the U.S. The clearance was issued by the Cardiovascular (CV) Advisory Committee in 2003, following a traditional review process.